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Proschan et al. [1] describe a “barely Bayesian design” (BBD) design currently being 
implemented to evaluate ZMapp as treatment for Ebola.  All trial patients receive an 
optimised standard of care, and are randomised equally between an experimental group (E) 
that additionally receives ZMapp and a control group (C) that does not.  The primary 
response is binary: survival to Day 28.  Interim analyses occur when 12 responses are 
received; then after every two new responses up to 40; finally after every 40 new responses 
up to 200.  These are total sample sizes.   
 Here, the probability of success (surviving until Day 28) on Treatment T is denoted by 
pT, T = E, C.  The BBD uses independent beta priors with parameters (1, 1) for pE and pC.  At 
each interim analysis, the posterior probability that E is superior to C is calculated as  = 
P(pE > pC).  If   0.999, the trial is stopped to claim that E is superior to C.  If   0.001, it is 
stopped to due to inferiority of E.  If the maximum sample size of 200 is reached and   
0.975, then superiority will be claimed for E. 
 An alternative design for comparing E with C in a randomised sequential trial can be 
based on a triangular test (TT) [2, 3].  Up to 20 interim analyses are conducted after every 25 
patient responses are received.  Suppose nT patients have received Treatment T, and ST have 
succeeded, T = E, C; nE + nC = n, SE + SC = S.   At each interim analysis, Z = (nCSE – nESC)/n and 
V = nEnCS(n – S)/n
3 are calculated.  The trial is stopped to claim E is better than C if Z ≥ 
6.3990 + 0.2105V, or to conclude that E is no better than C if Z ≤ −6.3990 + 0.6315V.  This 
particular TT forms the randomised component of a multi-stage approach [4, 5]: here it is 
considered in isolation.   
 Table 1 presents frequentist properties of both designs from million-fold simulations.  
For the TT the 25 new observations at each interim analysis alternate between one extra on 
E and one extra on C.  The TT is constructed to have a one-sided type I error rate () of 
0.025 and a power of 0.90 when the odds ratio is 2, and these properties are achieved quite 
accurately.  By contrast for BBD,  = 0.032 and 0.027 and powers are 0.684 and 0.574 for pC 
= 0.500 and 0.667 respectively.  Maximum sample sizes for BBD and TT are 200 and 500 
respectively, but average sample sizes are much closer.  Also given for TT is the probability 
that the final sample size is less than 300.  When Treatments E1, E2 and E3 are tested in turn 
against C, with pC = p1 = p2 while p3 takes a larger value (pi is the probability of success on Ei), 
the probability of correctly recommending only E3 is much greater for TT than BBD.  In the 
first case, average total sample sizes are similar.  Also shown are results from two “Matching 
TTs”, achieving the same  and power as the corresponding BBD.  These show substantial 
reductions in expected sample size relative to the BBD.  The TT is recommended for 
implementation, but the Matching TTs are not recommended due to their high  and low 
power. 
 The BBD fails to make use of opportunities afforded by the Bayesian approach, in 
particular using pre-existing data in constructing true representations of prior opinion.  Its 
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frequentist properties include  levels exceeding those conventionally adopted in phase III 
and disturbingly low power.  These deficiencies are compounded in a succession of 
comparisons.  The BBD assigns excessive resource to determining whether a treatment is 
merely ineffective or actually harmful.  The method does include a frequentist “advisory 
futility rule” but, because it is operated at the discretion of an Independent Data Monitoring 
Committee, it cannot be evaluated in simulations.   
 Any of a large number of existing group sequential approaches [2, 6] could have 
been adopted for the trial of ZMapp, or substituted for BBD in master protocols for 
evaluating a series of treatments.  There is no good reason for the introduction of a new 
method for these purposes.  The BBD does not, as it stands, allow for stratification or 
covariate adjustment in interim analyses, use of endpoints such as survival or ordered 
categories rather than binary, or for final valid frequentist analyses allowing for the interim 
analyses and for inclusion of data collected from patients still under treatment when the 
stopping criterion is met.  All these extensions could be developed, but they have already 
been created and implemented for existing methods such as the TT.  The TT as described 
has a first interim analysis after 25 patients, whereas the BBD starts after 12.  The TT could 
easily be altered to allow such early looks, but they are not especially useful.  To stop so 
early for safety according to BBD, not only have the results on E to be very bad, but those on 
C have to be very good.  By the time data from 12 patients can be analysed, more patients 
will have started study treatment, especially if the endpoint is at 28 days and trial 
recruitment is rapid.  Early safety signals are most likely to be detected by the Independent 
Data Monitoring Committee considering outcomes of patients on E, looking at their 
relationship to drug administration and without necessarily waiting the full 28 days. 
   Either the BBD or the TT can be used with or without preceding phase II trials to 
screen out poor treatments quickly: the advantage of doing so increases with the number of 
available treatments.  Such phase II trials could be randomised, but with higher type I error 
rates.  In exceptional circumstances, as encountered in the Ebola epidemic, they might be 
non-randomised [4, 5]. 
 The BBD is recommended by its authors for research in future serious epidemics.  
Results presented here suggest that serious consideration should be given to alternative 
designs in such circumstances. 
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Table 1: Properties of the BBD and TT for various combinations of pC and pE 
Results derived from million-fold simulations 
When pC = 0.500, the Matching TT has upper boundary Z = 4.450 + 0.2764V and lower boundary Z = 4.450 + 0.8292V, 
when pC = 0.667, the Matching TT has upper boundary Z = 4.144 + 0.3163V and lower boundary Z = 4.144 + 0.9489V, 
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that the total 
sample size  
 168 
0.500 0.333 ½ 0.000 180 0.000   97 1.000 0.000   59 1.000 
 0.500 1 0.032  198  0.025 184 0.923 0.031   98 0.947 
 0.667 2 0.684  180  0.899 227 0.810 0.686 136 0.756 
 0.800 4 0.995  112  1.000 121 0.999 0.996   87 0.979 
0.667 0.500 ½ 0.000  180  0.000   97 1.000 0.000   52 1.000 
 0.667 1 0.027  199  0.025 204 0.882 0.027   91 0.967 
 0.800 2 0.574  187  0.875 278 0.646 0.573 145 0.698 
 0.889 4 0.973  140  1.000 157 0.989 0.986 111 0.905 
3 experimental 
treatments 
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0.500 0.667 2 0.641 576 0.855 595 - 0.644 332 - 
0.667 0.800 2 0.543 585 0.832 686 -  0.542 327 - 
 
 
